|
1
|
Waerzeggers Y, Monfared P, Viel T, Faust A, Kopka K, Schäfers M, Tavitian B, Winkeler A, Jacobs A. Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol 2012; 84 Spec No 2:S168-78. [PMID: 22433827 DOI: 10.1259/bjr/66405626] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
A deeper understanding of the role of specific genes, proteins, pathways and networks in health and disease, coupled with the development of technologies to assay these molecules and pathways in patients, promises to revolutionise the practice of clinical medicine. Especially the discovery and development of novel drugs targeted to disease-specific alterations could benefit significantly from non-invasive imaging techniques assessing the dynamics of specific disease-related parameters. Here we review the application of imaging biomarkers in the management of patients with brain tumours, especially malignant glioma. In our other review we focused on imaging biomarkers of general biochemical and physiological processes related with tumour growth such as energy, protein, DNA and membrane metabolism, vascular function, hypoxia and cell death. In this part of the review, we will discuss the use of imaging biomarkers of specific disease-related molecular genetic alterations such as apoptosis, angiogenesis, cell membrane receptors and signalling pathways and their application in targeted therapies.
Collapse
Affiliation(s)
- Y Waerzeggers
- European Institute for Molecular Imaging, Westfaelische Wilhelms-University, Muenster, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
|
2
|
Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG. SPECT and PET Imaging of EGF Receptors with Site-Specifically Labeled EGF and Dimeric EGF. Bioconjug Chem 2009; 20:742-9. [DOI: 10.1021/bc800443w] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Zoya Levashova
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| | - Marina V. Backer
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| | - George Horng
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| | - Dean Felsher
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| | - Joseph M. Backer
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| | - Francis G. Blankenberg
- Department of Radiology/MIPS, Stanford University School of Medicine, Stanford, California 94305, Sibtech, Inc., Brookfield, Connecticut 06804, and Department of Medicine/Oncology, Stanford University School of Medicine, Stanford, California 94305
| |
Collapse
|
|
3
|
Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 2007; 35:186-208. [PMID: 17846765 DOI: 10.1007/s00259-007-0560-9] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2007] [Accepted: 07/20/2007] [Indexed: 12/23/2022]
Abstract
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases controls critical pathways involved in epithelial cell differentiation, growth, division, and motility. Alterations and disruptions in the function of the HER-kinase axis can lead to malignancy. Many therapeutic agents targeting the HER-kinase axis are approved for clinical use or are in preclinical/clinical development. The ability to quantitatively image the HER-kinase axis in a noninvasive manner can aid in lesion detection, patient stratification, new drug development/validation, dose optimization, and treatment monitoring. This review summarizes the current status in multimodality imaging of the HER-kinase axis using PET, SPECT, optical, and MR imaging. The targeting ligands used include small-molecule tyrosine kinase inhibitors, peptides, proteins, antibodies, and engineered antibody fragments. EGFR and HER2 imaging have been well documented in the past, and imaging of HER3, HER4, HER heterodimers, and HER-kinase mutants deserves significant research effort in the future. Successful development of new HER-kinase-targeted imaging agents with optimal in vivo stability, targeting efficacy, and desirable pharmacokinetics for clinical translation will enable maximum benefit in cancer patient management.
Collapse
Affiliation(s)
- Weibo Cai
- The Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA.
| | | | | |
Collapse
|